Solid Organ Transplantation

Area of Science:

• Hematology
• Transplant Surgery
• Oncology

Background:

• Light chain (AL) amyloidosis poses significant challenges to patient survival.
• Limited organ involvement is crucial for successful treatment strategies.
• Restoration of cardiac function via transplantation is key for further therapeutic options.

Purpose of the Study:

• To evaluate the efficacy of combined organ transplantation and disease-directed therapies in AL amyloidosis.
• To explore strategies for improving organ availability for AL amyloidosis patients.
• To address concerns regarding graft recurrence and disease progression.

Main Methods:

• Selection of patients with AL amyloidosis and limited organ involvement.
• Utilizing directed-donor, exchange, and extended-donor organ programs for transplantation.
• Administering high-dose therapy and autologous stem cell transplantation post-transplant.
• Employing plasma cell-directed therapies to manage disease recurrence and progression.

Main Results:

• Combined approach can lead to long-term survival in select AL amyloidosis patients.
• Organ transplantation facilitates access to critical disease-modifying treatments.
• Improved organ availability through various transplantation programs enhances treatment options.

Conclusions:

• Organ transplantation combined with hematologic disease control offers a viable path to long-term survival for select AL amyloidosis patients.
• Effective management of plasma cell disorders is essential for mitigating risks of graft recurrence and disease progression.